Adamis Pharma (ADMP) Receives a Hold from B.Riley FBR


B.Riley FBR analyst Andrew D’silva maintained a Hold rating on Adamis Pharma (ADMP) today and set a price target of $2.50. The company’s shares opened today at $2.95.

D’silva observed:

“Several notable events have taken place since our last update note on Adamis Pharmaceuticals (ADMP); most notably, AMC yesterday, 1/16, Sandoz, ADMP’s domestic commercialization partner for Symjepi, announced the product’s commercial launch. As a result, we anticipate trading will be extremely volatile in the coming days as the market digests the announcement.”

According to TipRanks.com, D’silva is a 4-star analyst with an average return of 8.6% and a 38.5% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Imprimis Pharmaceuticals, and Oramed Pharmaceuticals.

Currently, the analyst consensus on Adamis Pharma is a Strong Buy with an average price target of $6.50.

See today’s analyst top recommended stocks >>

Based on Adamis Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.88 million. In comparison, last year the company had a GAAP net loss of $8.03 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamis Pharmaceuticals Corp. is a biopharmaceutical company which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.. Its activities include the combination of pharmaceuticals and biotechnology to produce medicines for patients, and physicians.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts